NYSE - Nasdaq Real Time Price USD

Dr. Reddy's Laboratories Limited (RDY)

71.49

-0.66

(-0.91%)

At close: 4:00 PM EDT

72.00

+0.51

(+0.71%)

After hours: 5:26 PM EDT

Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India

Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c

GlobeNewswire last month

RDY
-0.91%
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK

HYDERABAD, India, March 19, 2024--Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).

Business Wire last month

RDY
-0.91%
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks last month

RDY
-0.91%
Why Doctor Reddy's (RDY) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 2 months ago

RDY
-0.91%
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 2 months ago

RDY
-0.91%
Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2024 Earnings Call Transcript

Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2024 Earnings Call Transcript January 30, 2024 Dr. Reddy’s Laboratories Limited isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, good day, and welcome to the Dr. Reddy’s Q3 FY ’24 Earnings […]

Insider Monkey 2 months ago

RDY
-0.91%
Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates

Dr. Reddy's (RDY) reports better-than-expected fiscal third-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.

Zacks 2 months ago

RDY
-0.91%
Dr. Reddy’s Q3 & 9M FY24 Financial Results

HYDERABAD, India, January 31, 2024--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2023.

Business Wire 2 months ago

RDY
-0.91%
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands

HYDERABAD, India & PRINCETON, N.J., January 03, 2024--Dr. Reddy's announces the acquisition of MenoLabs®, a leading women’s health and dietary supplements portfolio of brands.

Business Wire 3 months ago

RDY
-0.91%
Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index

HYDERABAD, India, December 14, 2023--Dr. Reddy’s has won back-to-back global recognitions for its commitment and progress on sustainability and Environment Social and Governance agenda.

Business Wire 4 months ago

RDY
-0.91%
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)

HOUSTON & HYDERABAD, India & BASEL, Switzerland, December 06, 2023--Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy’s"), and Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya"), today announced that they have entered into a development and license agreement (the "Agreement") for the development and commercialization of COYA 302, an investigatio

Business Wire 4 months ago

COYA

RDY
-0.91%
Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates

Dr. Reddy's (RDY) reports better-than-expected fiscal second-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.

Zacks 5 months ago

ANIX

RDY
-0.91%
Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q2 2024 Earnings Call Transcript

Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q2 2024 Earnings Call Transcript October 27, 2023 Dr. Reddy’s Laboratories Limited beats earnings expectations. Reported EPS is $1.07, expectations were $0.88. Operator: Ladies and gentlemen, good day, and welcome to the Dr. Reddy’s Q2 FY ’24 Earnings Conference Call. [Operator Instructions]. Please note that this conference is being recorded. […]

Insider Monkey 5 months ago

RDY
-0.91%
Dr. Reddy’s Q2 FY24 Financial Results

HYDERABAD, India, October 27, 2023--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter ended Sep 30, 2023.

Business Wire 5 months ago

RDY
-0.91%
All You Need to Know About Doctor Reddy's (RDY) Rating Upgrade to Strong Buy

Doctor Reddy's (RDY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks 5 months ago

RDY
-0.91%
3 Reasons Growth Investors Will Love Doctor Reddy's (RDY)

Doctor Reddy's (RDY) could produce exceptional returns because of its solid growth attributes.

Zacks 6 months ago

RDY
-0.91%
Doctor Reddy's (RDY) Loses -6.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Doctor Reddy's (RDY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 6 months ago

RDY
-0.91%
Here is Why Growth Investors Should Buy Doctor Reddy's (RDY) Now

Doctor Reddy's (RDY) could produce exceptional returns because of its solid growth attributes.

Zacks 7 months ago

RDY
-0.91%
Looking for a Growth Stock? 3 Reasons Why Doctor Reddy's (RDY) is a Solid Choice

Doctor Reddy's (RDY) could produce exceptional returns because of its solid growth attributes.

Zacks 7 months ago

RDY
-0.91%
Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.

HYDERABAD, India, August 10, 2023--Dr. Reddy's Laboratories announces its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.

Business Wire 8 months ago

RDY
-0.91%

Performance Overview

Return	RDY	S&P BSE SENSEX
YTD	+2.75%	+2.07%
1-Year	+20.06%	+23.61%
3-Year	+7.65%	+53.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Dr. Reddy's Laboratories Limited (RDY)

Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India

Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK

Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term

Why Doctor Reddy's (RDY) is a Top Momentum Stock for the Long-Term

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2024 Earnings Call Transcript

Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates

Dr. Reddy’s Q3 & 9M FY24 Financial Results

Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands

Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index

Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates

Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q2 2024 Earnings Call Transcript

Dr. Reddy’s Q2 FY24 Financial Results

All You Need to Know About Doctor Reddy's (RDY) Rating Upgrade to Strong Buy

3 Reasons Growth Investors Will Love Doctor Reddy's (RDY)

Doctor Reddy's (RDY) Loses -6.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Here is Why Growth Investors Should Buy Doctor Reddy's (RDY) Now

Looking for a Growth Stock? 3 Reasons Why Doctor Reddy's (RDY) is a Solid Choice

Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.

Performance Overview